Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EFANYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFAiShares MSCI EAFE ETF$82.46-0.9%$81.57$73.91▼$85.19$57.94B0.8612.34 million shs14.23 million shsNVSNovartis$112.69+1.2%$107.92$92.35▼$120.92$227.70B0.531.49 million shs2.54 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFAiShares MSCI EAFE ETF0.00%-1.43%+1.29%+8.34%+3.02%NVSNovartis0.00%+0.52%+3.47%+14.54%+17.54%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEFAiShares MSCI EAFE ETFN/AN/AN/AN/AN/AN/AN/AN/ANVSNovartis2.3055 of 5 stars0.95.02.50.04.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEFAiShares MSCI EAFE ETF 0.00N/AN/AN/ANVSNovartis 1.80Reduce$123.389.48% UpsideCurrent Analyst Ratings BreakdownLatest NVS and EFA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/13/2025NVSNovartisUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/12/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight2/4/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy2/3/2025NVSNovartisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEFAiShares MSCI EAFE ETFN/AN/AN/AN/AN/AN/ANVSNovartis$51.72B4.45$11.24 per share10.03$21.59 per share5.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEFAiShares MSCI EAFE ETFN/AN/A17.21∞N/AN/AN/AN/AN/ANVSNovartis$11.94B$5.8819.1712.791.7023.56%37.24%15.85%4/22/2025 (Estimated)Latest NVS and EFA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/ANVSNovartis$2.07N/AN/AN/AN/AN/A1/31/2025Q4 2024NVSNovartis$1.80$1.98+$0.18$1.41$12.86 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEFAiShares MSCI EAFE ETF$2.452.97%N/AN/AN/ANVSNovartis$2.512.23%+5.34%42.69%N/ALatest NVS and EFA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEFAiShares MSCI EAFE ETFN/AN/AN/ANVSNovartis0.481.040.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEFAiShares MSCI EAFE ETF79.80%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipEFAiShares MSCI EAFE ETFN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEFAiShares MSCI EAFE ETFN/A702.60 millionN/ANot OptionableNVSNovartis101,7002.04 billion2.04 billionOptionableNVS and EFA HeadlinesRecent News About These CompaniesTucker Asset Management LLC Boosts Stake in Novartis AG (NYSE:NVS)March 30 at 7:17 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Acquired by LPL Financial LLCMarch 30 at 4:14 AM | marketbeat.comFinancial Engines Advisors L.L.C. Purchases Shares of 3,640 Novartis AG (NYSE:NVS)March 29 at 5:12 AM | marketbeat.comNovartis AG (NYSE:NVS) Receives Average Rating of "Reduce" from BrokeragesMarch 29 at 4:32 AM | marketbeat.comAmerican Century Companies Inc. Has $44.12 Million Stake in Novartis AG (NYSE:NVS)March 29 at 4:10 AM | marketbeat.comFDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, PluvictoMarch 28 at 3:39 PM | appliedclinicaltrialsonline.comFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancerMarch 28 at 12:52 PM | globenewswire.comHere's Why Novartis (NVS) is a Strong Value StockMarch 28 at 10:40 AM | zacks.comNovartis AG (NYSE:NVS) Shares Sold by Loomis Sayles & Co. L PMarch 28 at 6:48 AM | marketbeat.comProficio Capital Partners LLC Buys Shares of 2,312 Novartis AG (NYSE:NVS)March 28 at 3:20 AM | marketbeat.comCongress Wealth Management LLC DE Sells 22,499 Shares of Novartis AG (NYSE:NVS)March 27 at 4:48 AM | marketbeat.comWambolt & Associates LLC Has $2.59 Million Holdings in Novartis AG (NYSE:NVS)March 26, 2025 | marketbeat.comNovartis put volume heavy and directionally bearishMarch 26, 2025 | markets.businessinsider.comCoreFirst Bank & Trust Buys Shares of 2,310 Novartis AG (NYSE:NVS)March 26, 2025 | marketbeat.comNovartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3GMarch 25, 2025 | pmlive.com5 Large Drug Stocks to Watch as Industry RecoversMarch 25, 2025 | zacks.comMill Capital Management LLC Cuts Stock Position in Novartis AG (NYSE:NVS)March 25, 2025 | marketbeat.comNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisMarch 25, 2025 | globenewswire.comChinese VP meets Swire Pacific Limited chairman, Novartis CEOMarch 24, 2025 | chinaview.cnLooking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical NamesMarch 24, 2025 | zacks.comWatch These 5 AI-Powered Healthcare Bigwigs for Portfolio GainsMarch 24, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS and EFA Company DescriptionsiShares MSCI EAFE ETF NYSEARCA:EFA$82.46 -0.74 (-0.89%) Closing price 03/28/2025 04:10 PM EasternExtended Trading$82.25 -0.21 (-0.25%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares MSCI EAFE ETF, formerly iShares MSCI EAFE Index Fund (the Fund), is an exchange-traded fund. The Fund's investment objective is to seek investment results that correspond to the price and yield performance of its underlying index, MSCI EAFE Index (the Index). The Index has been developed by MSCI Inc. as an equity benchmark for its international stock performance. The Index includes stocks from Europe, Australasia and the Far East. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.Novartis NYSE:NVS$112.69 +1.29 (+1.16%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$113.99 +1.30 (+1.15%) As of 03/28/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
